Combination ovarian test boosts response to therapy
This article was originally published in Clinica
By combining the actions of two assays, a team at Yale School of Medicine in Connecticut says it could double the response rate of ovarian cancer patients to drug therapy. The exclusive licensee of the new combination assay, Precision Therapeutics, told Clinica that a product could be available by 2007, following the completion of a prospective clinical trial scheduled to begin later this year.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.